Thor Straten P - Search Results

1

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM. Andersen R, et al. Among authors: thor straten p. Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006492

2

Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas.

Thor Straten P, Schøller J, Hou-Jensen K, Zeuthen J. Thor Straten P, et al. Int J Cancer. 1994 Jan 2;56(1):78-86. doi: 10.1002/ijc.2910560115. Int J Cancer. 1994. PMID: 8262682

3

In situ T cells in melanoma.

thor Straten P, Becker JC, Guldberg P, Zeuthen J. thor Straten P, et al. Cancer Immunol Immunother. 1999 Oct;48(7):386-95. doi: 10.1007/s002620050591. Cancer Immunol Immunother. 1999. PMID: 10501852 Free PMC article. Review.

4

Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.

thor Straten P, Kirkin AF, Siim E, Dahlström K, Drzewiecki KT, Seremet T, Zeuthen J, Becker JC, Guldberg P. thor Straten P, et al. Clin Immunol. 2000 Aug;96(2):94-9. doi: 10.1006/clim.2000.4890. Clin Immunol. 2000. PMID: 10900156

5

Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.

Schrama D, Andersen MH, Terheyden P, Schrøder L, Pedersen LO, thor Straten P, Becker JC. Schrama D, et al. Among authors: thor straten p. Cancer Res. 2001 Jan 15;61(2):493-6. Cancer Res. 2001. PMID: 11212239

6

In situ cytokine therapy: redistribution of clonally expanded T cells.

thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC. thor Straten P, et al. Eur J Immunol. 2001 Jan;31(1):250-8. doi: 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.0.CO;2-8. Eur J Immunol. 2001. PMID: 11265641 Free article.

7

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Andersen MH, et al. Among authors: thor straten p. Cancer Res. 2001 Aug 15;61(16):5964-8. Cancer Res. 2001. PMID: 11507035

8

Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report.

Pedersen LØ, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Bröcker EB, Becker JC. Pedersen LØ, et al. Among authors: thor straten p. J Invest Dermatol. 2002 Apr;118(4):595-9. doi: 10.1046/j.1523-1747.2002.01698.x. J Invest Dermatol. 2002. PMID: 11918704 Free article.

9

Identification of novel survivin-derived CTL epitopes.

Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Reker S, et al. Among authors: thor straten p. Cancer Biol Ther. 2004 Feb;3(2):173-9. doi: 10.4161/cbt.3.2.611. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14726703

10

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. Andersen MH, et al. Among authors: thor straten p. Semin Cancer Biol. 2003 Dec;13(6):449-59. doi: 10.1016/j.semcancer.2003.09.009. Semin Cancer Biol. 2003. PMID: 15001164 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page